Kobayashi H, Saito H, Kitano K, Kiyosawa K, Gaun S, Aoki K, Narita A, Watanabe M, Uchimaru K, Motokura T
Department of Internal Medicine, Nagano Red Cross Hospital, Japan.
Acta Haematol. 1995;94(4):199-203. doi: 10.1159/000204010.
The t(11;14)(q13;q32) chromosomal translocation is associated with several B-cell lymphoproliferative disorders and is thought to result in upregulation of expression of PRAD1/cyclin D1 proto-oncogene. A patient with multiple myeloma of IgG kappa-type with t(11;14)(q13;q32) is now shown to overexpress PRAD1. The clinical stage of the disease was advanced (IIIA), with a myeloma cell count of 94.6% in the bone marrow. Chromosomal analysis of bone marrow cells showed t(11;14)(q13;q32) in five of 20 metaphases as well as other karyotypic features. Northern blot analysis of RNA prepared from myeloma cells revealed overexpression of PRAD1. Multiple myeloma with t(11;14)(q13;q32) has been associated with an aggressive clinical course. Although neither myeloma cells in the peripheral blood nor extramedullary lesions were apparent in the present patient, the myeloma was refractory to several chemotherapeutic regimens from the beginning. Detection of PRAD1 expression may offer an easier alternative to cytogenetic analysis in myeloma and is a potentially useful indicator of a poor prognosis.
t(11;14)(q13;q32)染色体易位与多种B细胞淋巴增殖性疾病相关，被认为会导致PRAD1/细胞周期蛋白D1原癌基因的表达上调。现显示一名患有IgG κ型伴t(11;14)(q13;q32)的多发性骨髓瘤患者PRAD1过表达。该疾病的临床分期为晚期（IIIA期），骨髓中骨髓瘤细胞计数为94.6%。对骨髓细胞进行染色体分析显示，在20个中期细胞中有5个出现t(11;14)(q13;q32)以及其他核型特征。对骨髓瘤细胞制备的RNA进行Northern印迹分析显示PRAD1过表达。伴t(11;14)(q13;q32)的多发性骨髓瘤与侵袭性临床病程相关。尽管该患者外周血中未见骨髓瘤细胞，也无髓外病变，但骨髓瘤从一开始就对多种化疗方案耐药。检测PRAD1表达可能为骨髓瘤的细胞遗传学分析提供一种更简便的替代方法，并且是预后不良的一个潜在有用指标。
